Geneos Therapeutics Announces Another Complete Response in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer
To Date, Four Patients Are Now Cancer Free Out of 23 Evaluable
To Date, Four Patients Are Now Cancer Free Out of 23 Evaluable
Overall Response Rate 30.4 Percent in 23 Evaluable Patients Including Two Complete Responses and a Third Cancer-Free Patient
Encouraging Safety and Efficacy Data from Ongoing GT-30 Study in Second-Line HCC
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma
Geneos Therapeutics announced positive preliminary results of its ongoing first-in-human trial.
Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC)
Geneos Therapeutics has closed its Series A1 round, raising $12 million in financing.
VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement.
Geneos Therapeutics announced that its personalized neoantigen-targeting vaccine, GNOS-PV02 (based on its proprietary GT-EPIC™ platform), will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).
VGXI and Geneos Therapeutics have entered into a long-term master supply agreement to establish small-scale and rapid turnaround production services ideally suited for the personalized therapy approach.